Varsetatug
Based on 1 Customer Validation
Varsetatug (CX-2051 antibody) is a humanized IgG1κ monoclonal antibody inhibitor targeting EpCAM/TROP1/CD326. Varsetatug serves as the antibody component of the ADC compound CX-2051. It can be used in research on cancers including breast cancer, prostate cancer and ovarian cancer.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 97%
- No. CAS: 3036004-28-8
- Peso molecular:155.116 kDa
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
Actividad biológica
Human IgG1 kappa
Human
EpCAM/TROP1/CD326
CX-2051 is a masked EpCAM antibody-drug conjugate (ADC) carrying a novel camptothecin-based topoisomerase I (Topo-I) payload, a linker, and an EpCAM-targeting antibody moiety (Varsetatug).
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
IgG1-kappa
ELISA, FACS, Functional assay
-
Loaded Varsetatug on ProA biosensor, can bind EpCAM/TROP1 Protein, Human (Biotinylated, HEK293, His-Avi, HY-P72367) with an affinity constant of 1.693E-07 M as determined in BLI assay.
Chemical Information
-
No. CAS 3036004-28-8
-
Appearance Liquid
-
Peso molecular 155.116 kDa
-
Color Colorless to light yellow
-
SMILES
N/A
-
Synonyms
CX-2051 antibody
-
Envío
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
-
Ficha de datos (257 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)